Cytochrome P-450 CYP2D6 Inhibitors

Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2D6.

Also Known As:

CYP2D6 Inhibitors; P450 CYP2D6 Inhibitors; CYP2D6 Inhibitors, P450; Cytochrome P 450 CYP2D6 Inhibitors; Inhibitor, CYP2D6; Inhibitors, CYP2D6; Inhibitors, P450 CYP2D6; CYP2D6 Inhibitor

Networked: 27 relevant articles (2 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Enzyme Inhibitors: 1659
      - Cytochrome P-450 Enzyme Inhibitors: 8
        Cytochrome P-450 CYP2D6 Inhibitors: 27
  - Metabolic Side Effects of Drugs and Substances: 5
    - Cytochrome P-450 Enzyme Inhibitors: 8
      - Cytochrome P-450 CYP2D6 Inhibitors: 27

Experts

1.	Goetz, Matthew P: 2 articles (01/2018 - 11/2011)
2.	Guchelaar, Henk-Jan: 2 articles (01/2018 - 05/2010)
3.	Ingle, James N: 2 articles (01/2018 - 11/2011)
4.	Schwab, Matthias: 2 articles (01/2018 - 10/2009)
5.	Zembutsu, Hitoshi: 2 articles (01/2018 - 02/2011)
6.	Flockhart, David A: 2 articles (11/2011 - 01/2005)
7.	Mushiroda, Taisei: 2 articles (11/2011 - 02/2011)
8.	Nakamura, Yusuke: 2 articles (11/2011 - 02/2011)
9.	Weinshilboum, Richard M: 2 articles (11/2011 - 01/2005)
10.	Lindbloom, Tori J: 1 article (09/2021)

Related Diseases

1.	Pain (Aches) 11/01/2016 - "Of 176 patients, 52 (29.5%) patients with information about non-pain concomitant medication had been prescribed at least one known CYP2D6 inhibitor. " 01/01/2019 - "This study demonstrated a clinically relevant decrease in the efficacy of tramadol when used for pain control in patients receiving a strong CYP2D6 inhibitor. " 01/01/2019 - "The objective was to determine whether a clinically relevant decrease in pain control is observed in patients taking scheduled tramadol concomitantly with a strong CYP2D6 inhibitor. " 01/01/2019 - "Secondary outcomes included mean pain scores, length of hospital stay, tramadol discontinuation rates, and prespecified subgroup analyses based on patient sex, race, and specific CYP2D6 inhibitor administered. "
2.	Mental Disorders (Mental Disorder) 04/01/2023 - " results indicated that coadministration of a CYP2D6 inhibitor is effective in increasing plasma exposure and prolonging the half-life of tipepidine and is useful for repositioning tipepidine as a treatment for psychiatric disorders." 03/01/2023 - "CYP2D6 substrates were categorized as those with the potential for increased risk of QT prolongation, with anticholinergic properties, with narrow therapeutic index (NTI), contraindicated or having a black box warning when used with CYP2D6 inhibitors, or used for depression or other psychiatric disease. "
3.	Breast Neoplasms (Breast Cancer) 04/01/2011 - "Type and strength of CYP2D6 inhibitors, as well as duration of concurrent use did not affect breast cancer recurrence. " 05/10/2010 - "No association between concomitant CYP2D6 inhibitor use and breast cancer recurrence was observed (adjusted hazard ratio [HR], 0.87; 95% CI, 0.42 to 1.79; P = .69). " 01/01/2014 - "This study also shows that tamoxifen and the CYP2D6 inhibitors are not only prescribed by physicians specialized in breast cancer; therefore, all physicians should be aware of this interaction." 07/01/2012 - "Breast cancer patients (n = 141) on adjuvant tamoxifen and not on any concomitant CYP2D6 inhibitors were recruited for the study. " 11/01/2011 - "We conducted a nested case-control study in the context of the NSABP P1 and P2 prevention trials to determine the impact of CYP2D6 genotype, CYP2D6 inhibitor use, and metabolizer status (CYP2D6 genotype combined with CYP2D6 inhibitor use), on breast cancer events. "
4.	Delirium 07/01/2009 - "A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium. "
5.	Drug-Related Side Effects and Adverse Reactions 11/01/2016 - "A total of 35 (19.9%) patients were identified as being at risk of an adverse drug reaction and 33 (18.75%) patients at risk of suboptimal analgesic response due to co-administration of CYP2D6 inhibitors. "

Related Drugs and Biologics

1.	Tramadol (K315)
2.	tipepidine
3.	Tamoxifen
4.	Cytochrome P-450 CYP2D6 (CYP2D6)
5.	Cytochrome P-450 CYP2D6 Inhibitors
6.	4-hydroxy-N-desmethyltamoxifen
7.	Paroxetine (Paxil)
8.	Flecainide (Tambocor)
9.	Enzymes
10.	Cytochrome P-450 CYP3A

Related Therapies and Procedures

1.	Therapeutics
2.	Length of Stay
3.	Drug Therapy (Chemotherapy)